§ Federal grant opportunity · RFA-AI-27-004
Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)
National Institutes of Health is accepting applications for Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional). The deadline is September 24, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- September 24, 2026
- Award range
- Award amount not published
- Eligibility
- Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- RFA-AI-27-004
Program overview
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for the Atopic Dermatitis Research Network (ADRN) program. The ADRN program will support Centers that integrate clinical and translational research to improve our understanding and management of atopic dermatitis with emphasis on chronic skin inflammation and the defense mechanisms of the skin.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 24, 2026, allowing time for registration and validation.
Related grant opportunities
- FY26 Bureau of Land Management Invasive and Noxious Plant Management - Bureau wide
- National Institute of General Medical Sciences Predoctoral Basic Biomedical Sciences Research Training Program (T32)
- Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
- ROSES25: B.2 Heliophysics Foundational Research
- Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.